OR WAIT null SECS
© 2022 MJH Life Sciences and BioPharm International. All rights reserved.
© 2022 MJH Life Sciences™ and BioPharm International. All rights reserved.
September 21, 2022
The Public-Private Partnership for Rare Neurodegenerative Diseases will work to enhance understanding and develop treatments for rare neurodegenerative diseases.
September 15, 2022
The growth of the biopharmaceuticals market is feeding back into economies and, in part, is driving the boom in life sciences and biotech ecosystems.
September 14, 2022
Emergence Therapeutics will work with Synaffix’s ADC technology platform to develop multiple ADCs against undisclosed targets.
September 09, 2022
Avance Clinical’s acquisition of C3 Research Associates expands its CRO services to North America.
September 08, 2022
In partnership with the University of Pittsburgh, ElevateBio will open its next manufacturing center in the city.
Roche’s acquisition of Good Therapeutics grants them rights to the company's conditionally activated PD-1-regulated IL-2 program.
September 07, 2022
Touchlight will expand Lonza’s end-to-end offering for mRNA manufacturing with an additional, differentiated source of DNA raw material.
September 02, 2022
Novo Nordisk’s $1.1 billion acquisition of Forma Therapeutics is intended to expand its sickle cell and rare blood disorder portfolio.
August 12, 2022
Merck, known as MSD outside of the United States and Canada, will collaborate with Cerevance to identify novel targets for Alzheimer’s disease.
August 10, 2022
Pfizer’s $5.4 billion acquisition of Global Blood Therapeutics is expected to strengthen its sickle cell disease portfolio.